Literature DB >> 9858061

Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells.

M D Srivastava1, B I Srivastava, B Brouhard.   

Abstract

Marijuana, a widely abused drug in the US, and its derivatives (cannabinoids) have been used in AIDS and cancer patients for treatment of intractable nausea and cachexia. Yet, objective investigations of the effect of cannabinoids on the human immune system are few. We investigated the effect of delta9 tetrahydrocannabinol (THC) and cannabidiol (CBD) on cytokine production in vitro by human leukemic T, B, eosinophilic and CD8+ NK cell lines as models. THC decreased constitutive production of IL-8, MIP-1alpha, MIP-1beta, and RANTES and phorbol ester stimulated production of TNF-alpha, GM-CSF and IFN-gamma by NK cells. It inhibited MIP-1beta in HTLV-1 positive B-cells but tripled IL-8, MIP-1alpha and MIP-1beta in B-cells and MIP-1beta in eosinophilic cells but doubled IL-8. Both cannabinoids strongly inhibited IL-10 production by HUT-78 T-cells. Results indicate that THC and nonpsychotropic CBD have complex lineage and derivative specific effects on cytokines consistent with previous animal studies. These effects while of potential benefits in some inflammatory/autoimmune diseases may worsen HIV infection, tumorigenesis and allergic inflammation in the lung.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9858061     DOI: 10.1016/s0162-3109(98)00041-1

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  57 in total

1.  Immunoactive cannabinoids: therapeutic prospects for marijuana constituents.

Authors:  S E Straus
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

Review 2.  Microbial infections, immunomodulation, and drugs of abuse.

Authors:  Herman Friedman; Catherine Newton; Thomas W Klein
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

Review 3.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

Review 4.  The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

Authors:  Britta Hahn
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

Review 5.  Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

Authors:  Orrin Devinsky; Maria Roberta Cilio; Helen Cross; Javier Fernandez-Ruiz; Jacqueline French; Charlotte Hill; Russell Katz; Vincenzo Di Marzo; Didier Jutras-Aswad; William George Notcutt; Jose Martinez-Orgado; Philip J Robson; Brian G Rohrback; Elizabeth Thiele; Benjamin Whalley; Daniel Friedman
Journal:  Epilepsia       Date:  2014-05-22       Impact factor: 5.864

Review 6.  Neuropsychological consequences of HIV and substance abuse: a literature review and implications for treatment and future research.

Authors:  Lisa R Norman; Michael Basso; Anil Kumar; Robert Malow
Journal:  Curr Drug Abuse Rev       Date:  2009-05

Review 7.  Cannabinoids as therapeutic agents for ablating neuroinflammatory disease.

Authors:  G A Cabral; L Griffin-Thomas
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-09       Impact factor: 2.895

8.  Chronic Δ(9)-Tetrahydrocannabinol Administration Reduces IgE(+)B Cells but Unlikely Enhances Pathogenic SIVmac251 Infection in Male Rhesus Macaques of Chinese Origin.

Authors:  Qiang Wei; Li Liu; Zhe Cong; Xiaoxian Wu; Hui Wang; Chuan Qin; Patricia Molina; Zhiwei Chen
Journal:  J Neuroimmune Pharmacol       Date:  2016-04-25       Impact factor: 4.147

9.  Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.

Authors:  T Bisogno; L Hanus; L De Petrocellis; S Tchilibon; D E Ponde; I Brandi; A S Moriello; J B Davis; R Mechoulam; V Di Marzo
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

Review 10.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

Authors:  Sean D McAllister; Liliana Soroceanu; Pierre-Yves Desprez
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-28       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.